A group meets for a presentation in a glass-walled conference room, while a woman talks on the phone in the background

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Jun 2026 | FROM AKERO THERAPEUTICS

Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial

Arun Sanyal, Mary Rinella, Doreen Chan, Sonja K Billes, Arian Zari, Tim Rolph, Mazen Noureddin ADA 2026

Jun 2026 | FROM AKERO THERAPEUTICS

Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH

Naga Chalasani, Erik J Tillman, Sonja K Billes, Tim Rolph, Mazen Noureddin Hepatology

May 2026 | FROM AKERO THERAPEUTICS

Efruxifermin improved digital pathology and noninvasive fibrosis measures in participants with MASH and advanced fibrosis or compensated cirrhosis: analysis of the HARMONY and SYMMETRY phase 2b trials

Jörn M Schattenberg, Mary E Rinella, Vlad Ratziu, Elaine Chng, Julian Lee, Yukti Choudhury, Doreen Chan, Erik Tillman, Dean Tai, Kitty Yale, Tim Rolph, Mazen Noureddin EASL 2026

May 2026 | FROM AKERO THERAPEUTICS

Study design, rationale, and baseline characteristics of the SYNCHRONY Real-World Trial: a phase 3 trial evaluating efruxifermin in participants with MASLD or MASH

Quentin M Anstee, Naga Chalasani, Reshma Shringarpure, Doreen Chan, Ali Moulton, Brittany de Temple, Mark Burch, Meena Jain, Kitty Yale, Mazen Noureddin EASL 2026

May 2026 | FROM AKERO THERAPEUTICS

FGF21 receptor agonism reverses steatosis by directing FFA to mitochondria and increasing their oxidation, without raising mtROS

Suyavaran Arumugam, Michail Kokkorakis, Tim Rolph, Erik J Tillman, Wajahat Mehal EASL 2026

Nov 2025 | FROM AKERO THERAPEUTICS

AI-powered histology analysis of HARMONY reveals efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH

Jörn M Schattenberg, Vlad Ratziu, Ylaine Gerardin, Lara Murray, Christina Jayson, Robert Egger, Geetika Singh, Alyson R. Warr, Jacqueline Brosnan-Cashman, Doreen Chan, Jimmie Zhang, Erica Fong, Brittany de Temple, Matt Minerva, Mark Burch, Kimberly Barrett, Reshma Shringarpure, Erik Tillman, Tim Rolph, Andrew Cheng, Kitty Yale, Mazen Noureddin AASLD 2025

Nov 2025 | FROM AKERO THERAPEUTICS

Efruxifermin reduced fibrosis and septa area by quantitive digital pathology in participants with compensated cirrhosis due to MASH: Results from the 96-week, placebo-controlled, Phase 2B SYMMETRY trial

Mary E Rinella, Yukti Choudhury, Galvin Gan, Elaine Chng, Cynthia Behling, Doreen Chan, Lynn Lipps, Erik J Tillman, Mark Burch, Sonja K Billes 4, Reshma Shringarpure, Tim Rolph, Dean Tai, Kitty Yale, Mazen Noureddin AASLD 2025

Aug 2025 | FROM AKERO THERAPEUTICS

Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Mazen Noureddin, Juan P Frias, Guy Neff, K Jean Lucas, Cynthia Behling, Pierre Bedossa, Julie Dubourg, Doreen Chan, Mark Burch, Erica Fong, Brittany de Temple, Matt Minerva, Kim Barrett, Reshma Shringarpure, Erik J Tillman, Tim Rolph, Andrew Cheng, Kitty Yale The Lancet

Close up of multichannel micropipette filling four small blue centrifuge tubes

Our comprehensive clinical program is designed to evaluate EFX as a potential treatment for MASH.

View Our Clinical Trials